Brief: Actinium Pharmaceuticals Announces Iomab-B Sierra Trial Database Lock
21/09/2022 12:48
Sept 21 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM PHARMACEUTICALS ANNOUNCES IOMAB-B SIERRA TRIAL
DATABASE
LOCK, PROVIDES CORPORATE UPDATE HIGHLIGHTING KEY UPCOMING
MILESTONES
* ACTINIUM PHARMACEUTICALS INC - ON TRACK TO REPORT TOPLINE
DATA
FROM PIVOTAL PHASE 3 SIERRA TRIAL FOR IOMAB-B IN Q4 2022
* ACTINIUM PHARMACEUTICALS - OVERALL SURVIVAL DATA FROM
ACTIMAB-A
CLAG-M COMBINATION TRIAL EXPECTED IN Q4 2022
* ACTINIUM - ADDITIONAL UPDATES ON COLLABORATIONS AND
PIPELINE
PROGRESS IN DEVELOPMENT OF ACTINIUM-225-BASED RADIOTHERAPIES
EXPECTED BY YEAR-END
* ACTINIUM PHARMACEUTICALS INC - PRIMARY ENDPOINT FOR SIERRA
TRIAL
IS DURABLE COMPLETE REMISSION (DCR) OF AT LEAST 180 DAYS
Source text for Eikon: ID:nPn84mWg6a
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities